AVEO Pharma

AVEO Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the advancement of therapeutics for oncology, and other areas of unmet medical need. Its product candidates include Tivozanib, Ficlatuzmab, AV-203, AV-380 and AV-353. The company was founded by Ronald A. DePinho, Lynda Chin, and Kenneth E. Weg on October 19, 2001 and is headquartered in Cambridge, MA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AVEO is a late-stage biopharmaceutical company focused on the discovery and development of targeted cancer therapeutics. AVEO's proprietary, integrated cancer biology platform enables the company to pursue highly efficient drug development strategies in oncology that increase the probability of clinical success and provides a discovery engine for high-value targets and therapies. This approach has resulted in a balanced pipeline of novel cancer therapies focused on well-validated targets (VEGFR, EGFR) and promising novel targets (HGF, FGFR, ErbB3 and NOTCH), as well as collaborations with Eli Lilly, Merck, OSI Pharmaceuticals, Schering-Plough, and Biogen Idec. The company was established in 2001 and is based in Cambridge, Massachusetts.

BOSTON, June 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the National Comprehensive Cancer Network® (NCCN) has elevated FOTIVDA® (tivozanib) to Category 1 status as a subsequent therapy for RCC patients who have received two or more prior therapies in the latest Kidney Cancer Treatment Guidelines released on June 17, 2022.

AVEO Oncology Announces Updated NCCN Clinical Practice Guidelines Elevate FOTIVDA® (tivozanib) to Category 1 Treatment for Relapsed or Refractory Advanced (R/R) Renal Cell Carcinoma (RCC) Patients

Exploratory long-term OS analyses of TIVO-3 continue to trend in favor of tivozanib, patients with PFS at 1 year demonstrated a 55% reduction in risk of death on tivozanib as compared to sorafenib

AVEO Oncology Presents Three Posters for Tivozanib at the 2022 ASCO Annual Meeting

AVEO is a mostly forgotten name that is seeing very good growth in their lead product FOTIVDA. Their share price has run lower from exuberant highs reached almost 5 years ago, even as their fundamentals and future seem to be getting more solid.

AVEO Pharmaceuticals Is Primed For A Breakout

BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 1:30 p.m. eastern time.

AVEO Oncology Announces Participation at the H.C. Wainwright Global Investment Conference

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO ) Q1 2022 Earnings Conference Call May 5, 2022 8:00 AM ET Company Participants Hans Vitzthum – LifeSci Advisors Michael Bailey – President and Chief Executive Officer Mike Ferraresso – Chief Commercial Officer Erick Lucera – Chief Financial Officer Jeb Ledell – Chief Operating Officer Conference Call Participants Colleen Kusy – Baird Andrew Berens – SVB Securities Soumit Roy – Jones Research Swayampakula Ramakanth – H.C. Wainwright Operator Good morning, and welcome to AVEO Oncology First Quarter 2022 Financial Results Conference Call.

AVEO Pharmaceuticals' (AVEO) CEO Michael Bailey on Q1 2022 Results - Earnings Call Transcript

AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates

– Total Q1 2022 Net Revenue of $20.9 Million including $20.1 Million of FOTIVDA ® (tivozanib) U.S. Net Product Revenue –

AVEO Oncology Reports First Quarter 2022 Financial Results

BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report first quarter 2022 financial results on Thursday, May 5, 2022. AVEO's management team will host a conference call and audio webcast at 8:30 a.m. ET on Thursday, May 5, 2022, to discuss the financial results and provide a business update.

AVEO Oncology to Announce First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 5, 2022

AVEO Pharmaceuticals Inc's (AVEO) CEO Michael Bailey on Q4 2021 Results - Earnings Call Transcript

AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates

– Total 2021 Net Revenue of $42.3 Million –

AVEO Oncology Reports Full Year and Fourth Quarter 2021 Financial Results

BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022. AVEO's management team will host a conference call and audio webcast at 8:30 a.m. ET on Monday, March 14, 2022, to discuss the financial results and provide a business update.

AVEO Oncology to Announce Full Year 2021 Financial Results and Host Conference Call and Webcast on March 14, 2022

Actinium Pharmaceuticals

NEW YORK and BOSTON, Feb. 22, 2022 /PRNewswire/ -- Actinium Pharmaceuticals, Inc.  (NYSE AMERICAN: ATNM) ("Actinium" or the "Company"), a leader in the development of targeted radiotherapies and AVEO Oncology (NASDAQ: AVEO) ("AVEO"), a commercial stage, oncology-focused biopharmaceutical company, today announced that they have entered into a research collaboration to develop and study a first-in-class antibody radio-conjugate (ARC) targeting ErbB3, also known as HER3. Actinium will utilize its AWE technology platform and extensive radiotherapy know-how to conjugate one of AVEO's ErbB3 targeted antibodies, with the potent alpha-emitting radioisotope Actinium-225 (Ac-225).

Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors

Five year follow-up data show FOTIVDA® (tivozanib) patients up to 5X more likely to experience long-term PFS compared to Nexavar® (sorafenib)

AVEO Oncology to Present Positive New Long-Term PFS Data from Phase 3 TIVO-3 Study of FOTIVDA® (tivozanib) in Third- and Fourth-Line Renal Cell Carcinoma

BOSTON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Thursday, February 17, 2022 at 9:20 a.m. eastern time.

AVEO Oncology Announces Participation at the 11th Annual SVB Leerink Global Healthcare Conference

First line cohort of the Phase 1b/2 DEDUCTIVE study demonstrates promising efficacy and tolerability of tivozanib plus durvalumab in first line HCC

AVEO Oncology Presents Three Posters for Tivozanib/Immunotherapy Combinations at the 2022 ASCO GI Cancers Symposium

WILMINGTON, Del. & BOSTON--(BUSINESS WIRE)--NiKang Therapeutics Inc. (“NiKang”), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company (“AVEO”) , today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate NKT2152, NiKang's small molecule that inhibits hypoxia induc

NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma

BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today highlighted its recent progress and outlook for 2022.

AVEO Oncology Highlights Recent Progress and 2022 Outlook

Manufacturing of Ficlatuzumab Clinical Supply to Commence in 2Q 2022; Initiation of Registrational Study in HPV Negative R/M HNSCC Expected in 1H 2023 Manufacturing of Ficlatuzumab Clinical Supply to Commence in 2Q 2022; Initiation of Registrational Study in HPV Negative R/M HNSCC Expected in 1H 2023

AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC

BOSTON, Dec. 22, 2021 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10th to Thursday, January 13th.

AVEO Oncology Announces Participation at the H.C. Wainwright Virtual BioConnect 2022 Conference

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced the appointment of Jeb Ledell as chief operating officer. In this role, he will be responsible for overseeing operational functions key to maximizing the Company's organizational efficiency and advancing its pipeline of products. “We are excited to welcome Jeb to the team during an important phase of AVEO's evolution as an integrated clinical development and com

AVEO Oncology Announces Appointment of Jeb Ledell as Chief Operating Officer

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences: Stifel 2021 Healthcare Conference Date: Monday, November 15 Time: 1:20 p.m. Eastern Time 4th Annual Evercore ISI Healthconx Conference Date: Tuesday, November 30 Time: 12:35 p.m. Eastern Time A webcast of the fireside chats, or the subsequent archived record

AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences

AVEO Pharmaceuticals, Inc. (AVEO) CEO Michael Bailey on Q3 2021 Results - Earning Call Transcript

BOSTON--(BUSINESS WIRE)--AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provided a business update. “During the third quarter, we continued to see strong commercial uptake for FOTIVDA®, further underscoring the significant unmet medical need that exists in the indicated treatment population. FOTIVDA has been well received by oncologists treating relapsed or refracto

AVEO Oncology Reports Third Quarter 2021 Financial Results and Provides Business Update

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for AVEO Pharma Stock (AVEO)